18F-fluoroestradiol (18F-FES) PET/CT for guiding first-line treatment in patients with HR + /HER2- metastatic breast cancer: impact on progression free survival.
Saved in:
| Title: | 18F-fluoroestradiol (18F-FES) PET/CT for guiding first-line treatment in patients with HR + /HER2- metastatic breast cancer: impact on progression free survival. |
|---|---|
| Authors: | Xie, Yizhao1,2 (AUTHOR), Chen, Yifan1,2 (AUTHOR), Liu, Cheng2,3,4,5 (AUTHOR), Zhao, Yannan1,2 (AUTHOR), Gong, Chengcheng1,2 (AUTHOR), Lin, Shuyi2,3,4,5 (AUTHOR), Song, Shaoli2,3,4,5 (AUTHOR) shaoli-song@163.com, Wang, Biyun1,2 (AUTHOR) wangbiyun0107@hotmail.com, Yang, Zhongyi2,3,4,5 (AUTHOR) yangzhongyi21@163.com |
| Source: | European Journal of Nuclear Medicine & Molecular Imaging. Dec2025, Vol. 53 Issue 1, p374-388. 15p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
